Nasdaq · Healthcare
BridgeBio Pharma, Inc. (BBIO)
As-reported financials and recent SEC filings for BridgeBio Pharma, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$502.1M
Net income
$-732.9M
Net margin
-146.0%
Diluted EPS
$-3.78
ROE
35.3%
P/E (TTM)
—
Market cap
$13.76B
Debt / equity
-1.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $502.1M | $221.9M | $9.3M | $77.6M | $69.7M |
| Gross profit | — | — | $6.9M | — | — |
| Operating income | $-523.4M | $-593.0M | $-607.4M | $-512.2M | $-576.6M |
| Net income | $-732.9M | $-543.3M | $-653.3M | $-484.7M | $-586.5M |
| Diluted EPS | $-3.78 | $-2.88 | $-3.95 | $-3.26 | $-3.90 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-26
View on EDGAR →1442026-06-24
View on EDGAR →1442026-06-24
View on EDGAR →42026-06-24
View on EDGAR →42026-06-24
View on EDGAR →42026-06-24
View on EDGAR →42026-06-24
View on EDGAR →42026-06-24
View on EDGAR →Go deeper on BBIO
Search BridgeBio Pharma, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.